Implication of β2-adrenergic receptor and miR-196a correlation in neurite outgrowth of LNCaP prostate cancer cells.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
04
2021
accepted:
13
06
2021
entrez:
30
6
2021
pubmed:
1
7
2021
medline:
19
11
2021
Statut:
epublish
Résumé
The β2-adrenergic receptor has been shown to be involved in neuroendocrine differentiation and to contribute to the development of aggressive prostate cancer. In this study we have investigated whether miR-196a plays a role in the regulation of the β2-adrenergic receptor in the LNCaP prostate cancer cell line. Our results show that the expression of miR-196a is elevated in LNCaP prostate cancer cells with reduced levels of β2-adrenergic receptor after stably transfection with three different shRNAs. Furthermore, treatment with β-blockers showed that this upregulation is strictly related to the low levels of β2-adrenergic receptor and not to the inhibition of the receptor signaling activity. Finally, we found that the reduced ability of LNCaP cells with low levels of β2-adrenergic receptor to initiate neuroendocrine differentiation under androgen depletion conditions is mediated by miR-196a. In conclusion, this study provides the rational for a role of miR-196a in the β2-adrenergic receptor mediated neuroendocrine differentiation of LNCaP prostate cancer cells.
Identifiants
pubmed: 34191854
doi: 10.1371/journal.pone.0253828
pii: PONE-D-21-12280
pmc: PMC8244869
doi:
Substances chimiques
ADRB2 protein, human
0
Adrenergic beta-2 Receptor Antagonists
0
MIRN196 microRNA, human
0
MicroRNAs
0
Receptors, Adrenergic, beta-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0253828Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cancer Res. 2008 Aug 1;68(15):6162-70
pubmed: 18676839
Theranostics. 2017 Jun 24;7(9):2452-2462
pubmed: 28744327
Cell Signal. 2011 Mar;23(3):507-15
pubmed: 20813184
Eur Urol. 2018 May;73(5):e134-e135
pubmed: 29452710
Oncol Lett. 2018 May;15(5):6063-6076
pubmed: 29616091
Cancer Cell. 2007 Nov;12(5):419-31
pubmed: 17996646
Sci Rep. 2018 Jan 31;8(1):1949
pubmed: 29386530
Mol Cancer Res. 2019 Nov;17(11):2154-2168
pubmed: 31395667
Cold Spring Harb Perspect Med. 2017 Sep 1;7(9):
pubmed: 28389515
Int J Mol Sci. 2018 May 04;19(5):
pubmed: 29734647
Asian J Androl. 2014 Jul-Aug;16(4):541-4
pubmed: 24589459
Oncotarget. 2016 Jan 12;7(2):1878-94
pubmed: 26646591
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
J Cancer. 2016 Mar 20;7(6):650-5
pubmed: 27076845
Asian J Androl. 2019 May-Jun;21(3):253-259
pubmed: 29848834
Prostate. 2008 Jul 1;68(10):1133-42
pubmed: 18454446
Mol Cancer. 2017 Oct 5;16(1):156
pubmed: 28982366
Mol Cell Biol. 2006 Nov;26(22):8371-84
pubmed: 16982692
Nat Rev Cancer. 2015 Dec;15(12):701-11
pubmed: 26563462
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
World J Mens Health. 2019 Sep;37(3):288-295
pubmed: 30209899
Oncogene. 2017 Mar;36(11):1525-1536
pubmed: 27641328
Genes Dev. 2004 Apr 15;18(8):862-76
pubmed: 15078817
Front Oncol. 2015 Apr 14;5:90
pubmed: 25927031
Prostate. 2020 Sep;80(12):1024-1037
pubmed: 32628792
Front Oncol. 2015 Jan 12;4:375
pubmed: 25629002
Cancer Res. 2016 Jul 1;76(13):3666-70
pubmed: 27325641
Adv Exp Med Biol. 2015;867:125-43
pubmed: 26530364
Oncotarget. 2017 Mar 21;8(12):19172-19191
pubmed: 27880728
Curr Cancer Drug Targets. 2018;18(10):929-944
pubmed: 29644941
Oncogene. 2020 Dec;39(49):7209-7223
pubmed: 33037409
PLoS One. 2015 Sep 16;10(9):e0137637
pubmed: 26376480
J Cell Mol Med. 2011 Jan;15(1):14-23
pubmed: 21091634
Nat Med. 2012 Jul;18(7):1136-41
pubmed: 22660636
Oncotarget. 2017 Jul 25;8(30):50240-50251
pubmed: 28445135